Xenon Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xenon Pharmaceuticals (XENE).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

17Buy

1Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$62Upside to Avg. PT+74.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Guggenheim	Delma Caiati	Assumes	Buy	$73
Sep 18, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$81→$70
Sep 18, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$71→$55
Sep 18, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$69→$64
Sep 18, 2026	Deutsche Bank	David Hoang	Downgrade	Buy→Hold	$90→$46
Sep 18, 2026	Needham	Serge Belanger	PT Cut	Buy	$78→$60
Sep 18, 2026	Baird	Brian Skorney	PT Cut	Outperform	$97→$90
Aug 7, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$82→$81
May 27, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$80→$82
May 12, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$77→$80
May 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$80→$82
May 8, 2026	Needham	Serge Belanger	PT Cut	Buy	$80→$78
Mar 16, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$64→$63
Mar 10, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$49→$68
Mar 10, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$47→$64
Mar 10, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$56→$90
Mar 10, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$53→$74
Mar 9, 2026	Needham	Serge Belanger	PT Raise	Buy	$58→$80
Mar 9, 2026	Baird	Brian Skorney	PT Raise	Outperform	$63→$97
Feb 27, 2026	Needham	Serge Belanger	PT Raise	Buy	$55→$58

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.

Benzinga Newsdesk

Xenon Stock Reaction Is Overblown: Analyst

Xenon Pharmaceuticals submits an FDA application for azetukalner for seizures while voluntarily pausing enrollment in depression trials.

Vandana Singh

PRO
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $81 to $70.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $71 to $55.

Benzinga Newsdesk

This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Analysts downgraded Magna, Franklin BSP, and more revising price targets for several.

Avi Kapoor

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.

Avi Kapoor

Xenon Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Xenon Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Xenon Stock Reaction Is Overblown: Analyst

PRO
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70

PRO
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55

This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

People Also Watch

People Also Watch

Xenon Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Xenon Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Xenon Stock Reaction Is Overblown: Analyst

PRORBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70

PROWedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55

This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

People Also Watch

People Also Watch

PRO
Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

PRO
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70

PRO
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55